Primary end point of treatment of NSCLC with PD-1 antibody of Baiji Shenzhou of "medical fast reading society" reached 3 stages

[January 22, 2020 / medical information list] patients with new pneumonia can enjoy special reimbursement policies; Nanyan technology has completed a round of financing of more than 100 million yuan; China has approved the first antibody coupled drug; GSK ADC drug has obtained the priority approval qualification of FDA; Johnson darzalex + VTD program has been approved by the European Union Daily fresh medicine news, speed reading club and you pay attention to! On the 21st, the state medical insurance bureau announced to further strengthen the guidance to the medical insurance departments in Hubei and other places, and required the national medical insurance system to do a good job of treatment guarantee according to the "two guarantees", so as to ensure that patients will not be treated in time due to cost problems, and that designated medical institutions will not be affected by the total medical insurance budget management provisions (state health insurance bureau) On the 21st, Shaanxi Provincial Food and Drug Administration released the first drug quality announcement in 2020, including 9 batches of Chinese herbal pieces and 1 batch of Chinese patent medicine (Shaanxi Provincial Drug Administration) Recently, the health insurance bureau of Hefei City, Anhui Province issued the notice on carrying out the major investigation of irregularities in designated medical institutions, saying that it decided to carry out the major investigation of irregularities in designated medical institutions in the city (Hefei medical insurance bureau) Nanyan technology recently announced that it has completed the B2 round financing of over 100 million yuan It is understood that this round of financing is led by BOC International, followed by shareholders such as LanChi venture capital, Haina Asia and Shidai investment (arterial network) On the 22nd, calidi biotherapeutics announced the completion of round a financing to prepare for the application of new drugs for clinical research in research and treatment It is reported that the company has long been committed to the development of oncolytic virus immunotherapy for a variety of refractory cancer patients (chuangjianhui) Today, Baiji Shenzhou announced that its anti-PD-1 antibody tirelizumab combined with two chemotherapy regimens was used in a critical phase 3 clinical trial for the first-line treatment of patients with squamous non-small cell lung cancer After evaluation by the independent review committee, it reached the main end point of improving the progression free survival period (Sina Medical News) On Monday, Roche kadcyla's listing application in China was officially approved by the State Drug Administration It is reported that the drug is the first antibody coupled drug approved for marketing in China (medicine cube) GlaxoSmithKline announced that FDA of the United States has granted it the priority to evaluate the antibody coupling drug bellantamab mafodotin targeting B cell mature antigen (BCMA) for the treatment of relapsed / refractory multiple myeloma patients (source of us and Chinese Medicine) Horizon therapeutics announced Tuesday that the US FDA has approved its innovative treatment tepezza for the treatment of thyroid ophthalmopathy It is reported that thyroid ophthalmopathy is a rare and progressive autoimmune disease that threatens vision (yaomingkant) Johnson & Johnson's Janssen Pharmaceutical recently announced that the European Commission has approved darzalex combined with bortezomib, thalidomide and dexamethasone as a first-line treatment for patients with newly diagnosed multiple myeloma who meet the conditions of autologous stem cell transplantation (Biovalley) Today, Evoke Pharma announced that the US FDA has accepted the new drug application of its Gimoti nasal spray, which is resubmit, and expects that FDA will make a reply in June 19th this year (yaomingkant)